EGF receptor uses SOS1 to drive constitutive activation of NF B in cancer cells
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
EGF receptor uses SOS1 to drive constitutive activation of NF B in cancer cells
Authors
Keywords
-
Journal
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Volume 111, Issue 32, Pages 11721-11726
Publisher
Proceedings of the National Academy of Sciences
Online
2014-07-29
DOI
10.1073/pnas.1412390111
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Characteristics of Lung Cancers Harboring NRAS Mutations
- (2013) K. Ohashi et al. CLINICAL CANCER RESEARCH
- Activation of Extracellular Signal-Regulated Kinase but Not of p38 Mitogen-Activated Protein Kinase Pathways in Lymphocytes Requires Allosteric Activation of SOS
- (2013) J. E. Jun et al. MOLECULAR AND CELLULAR BIOLOGY
- EGFR-Induced and PKCε Monoubiquitylation-Dependent NF-κB Activation Upregulates PKM2 Expression and Promotes Tumorigenesis
- (2012) Weiwei Yang et al. MOLECULAR CELL
- Sos-mediated cross-activation of wild-type Ras by oncogenic Ras is essential for tumorigenesis
- (2012) Hao-Hsuan Jeng et al. Nature Communications
- Understanding SOS (Son of Sevenless)
- (2011) Stéphane Pierre et al. BIOCHEMICAL PHARMACOLOGY
- CARMA3 is Crucial for EGFR-Induced Activation of NF- B and Tumor Progression
- (2011) T. Jiang et al. CANCER RESEARCH
- E7080 Suppresses Hematogenous Multiple Organ Metastases of Lung Cancer Cells with Nonmutated Epidermal Growth Factor Receptor
- (2011) H. Ogino et al. MOLECULAR CANCER THERAPEUTICS
- FAS and NF-κB signalling modulate dependence of lung cancers on mutant EGFR
- (2011) Trever G. Bivona et al. NATURE
- Nuclear PKM2 regulates β-catenin transactivation upon EGFR activation
- (2011) Weiwei Yang et al. NATURE
- NF-κB is 25
- (2011) David Baltimore NATURE IMMUNOLOGY
- Ligand-dependent EGFR activation induces the co-expression of IL-6 and PAI-1 via the NFkB pathway in advanced-stage epithelial ovarian cancer
- (2011) C Alberti et al. ONCOGENE
- FER tyrosine kinase (FER) overexpression mediates resistance to quinacrine through EGF-dependent activation of NF- B
- (2011) C. Guo et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Oncogenic EGFR Signaling Activates an mTORC2-NF- B Pathway That Promotes Chemotherapy Resistance
- (2011) K. Tanaka et al. Cancer Discovery
- Therapeutic targeting of epidermal growth factor receptor in human cancer: successes and limitations
- (2011) Jill Wykosky et al. Chinese Journal of Cancer
- Inhibition of NF-κB Signaling by Quinacrine Is Cytotoxic to Human Colon Carcinoma Cell Lines and Is Synergistic in Combination with Tumor Necrosis Factor-related Apoptosis-inducing Ligand (TRAIL) or Oxaliplatin
- (2010) Tanvi S. Jani et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Overexpression of Kinesins Mediates Docetaxel Resistance in Breast Cancer Cells
- (2009) S. De et al. CANCER RESEARCH
- Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer
- (2009) P. S. Hammerman et al. CLINICAL CANCER RESEARCH
- Validation-based insertional mutagenesis identifies lysine demethylase FBXL11 as a negative regulator of NF B
- (2009) T. Lu et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Shared Principles in NF-κB Signaling
- (2008) Matthew S. Hayden et al. CELL
- NF-κB in carcinoma therapy and prevention
- (2008) Matthew Brown et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- Computational modelling reveals feedback redundancy within the epidermal growth factor receptor/extracellular-signal regulated kinase signalling pathway
- (2008) R.J. Orton et al. IET Systems Biology
- Lung adenocarcinoma: guiding EGFR-targeted therapy and beyond
- (2008) Marc Ladanyi et al. MODERN PATHOLOGY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started